Should I buy or sell PROCEPT BioRobotics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PROCEPT BioRobotics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRCT shares. View PRCT analyst ratings or view top-rated stocks .

What is PROCEPT BioRobotics' stock price target for 2024?

6 Wall Street research analysts have issued twelve-month price objectives for PROCEPT BioRobotics' stock. Their PRCT share price targets range from $37.00 to $58.00. On average, they anticipate the company's stock price to reach $45.60 in the next year. This suggests that the stock has a possible downside of 10.7%. View analysts price targets for PRCT or view top-rated stocks among Wall Street analysts .

How have PRCT shares performed in 2024?

PROCEPT BioRobotics' stock was trading at $41.91 at the beginning of the year. Since then, PRCT stock has increased by 21.9% and is now trading at $51.08. View the best growth stocks for 2024 here .

When is PROCEPT BioRobotics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our PRCT earnings forecast .

How can I listen to PROCEPT BioRobotics' earnings call?

PROCEPT BioRobotics will be holding an earnings conference call on Wednesday, May 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link .

How were PROCEPT BioRobotics' earnings last quarter?

PROCEPT BioRobotics Co. (NASDAQ:PRCT) issued its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.10. The company had revenue of $43.58 million for the quarter, compared to analysts' expectations of $41.79 million. PROCEPT BioRobotics had a negative net margin of 77.75% and a negative trailing twelve-month return on equity of 46.59%. The company's revenue was up 83.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.56) EPS.

What ETFs hold PROCEPT BioRobotics' stock?

ETFs with the largest weight of PROCEPT BioRobotics (NASDAQ:PRCT) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE) , ALPS Disruptive Technologies ETF (DTEC) , Global X Robotics & Artificial Intelligence Thematic ETF (BOTZ) and BNY Mellon Innovators ETF (BKIV) . iShares U.S. Medical Devices ETF (IHI) .

What guidance has PROCEPT BioRobotics issued on next quarter's earnings?

PROCEPT BioRobotics issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $210.0 million-$210.0 million, compared to the consensus revenue estimate of $204.5 million.

When did PROCEPT BioRobotics IPO?

PROCEPT BioRobotics (PRCT) raised $126 million in an initial public offering on Wednesday, September 15th 2021. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share.

Who are PROCEPT BioRobotics' major shareholders?

PROCEPT BioRobotics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.39%) and Diversified Trust Co (0.03%). Insiders that own company stock include Alaleh Nouri, Frederic H Moll, Global Investors Lp Viking, Hisham Shiblaq, Kevin Waters, Morgan Colby Wood, Reza Zadno and Thomas M Krummel. View institutional ownership trends .

How do I buy shares of PROCEPT BioRobotics?

Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PRCT

PROCEPT BioRobotics (PRCT) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free PRCT Stock Alerts

$51.08

-0.71 (-1.37%)

(As of 04/18/2024 ET)

Compare

Today's Range: $50.96
▼
$53.93
50-Day Range: $45.73
▼
$53.32
52-Week Range: $24.83
▼
$54.50

Volume: 635,935 shs
Average Volume: 496,700 shs
Market Capitalization: $2.60 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $45.60

Get PROCEPT BioRobotics alerts:

PROCEPT BioRobotics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 10.7% Downside
$45.60 Price Target
Short Interest: Bearish
9.58% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.39
Based on 4 Articles This Week
Insider Trading: Selling Shares
$4.65 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.00) to ($1.50) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.46 out of 5 stars

Medical Sector

875th out of 918 stocks

Surgical & Medical Instruments Industry

86th out of 91 stocks

1.5

Analyst's Opinion

Consensus Rating
PROCEPT BioRobotics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
PROCEPT BioRobotics has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
9.58% of the float of PROCEPT BioRobotics has been sold short.
Short Interest Ratio / Days to Cover
PROCEPT BioRobotics has a short interest ratio ("days to cover") of 9.3.
Change versus previous month
Short interest in PROCEPT BioRobotics has recently increased by 12.86%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
PROCEPT BioRobotics does not currently pay a dividend.
Dividend Growth
PROCEPT BioRobotics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PRCT.

1.9

News and Social Media Coverage

News Sentiment
PROCEPT BioRobotics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for PROCEPT BioRobotics this week, compared to 3 articles on an average week.
Search Interest
Only 1 people have searched for PRCT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added PROCEPT BioRobotics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PROCEPT BioRobotics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,653,720.00 in company stock.
Percentage Held by Insiders
19.60% of the stock of PROCEPT BioRobotics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
89.46% of the stock of PROCEPT BioRobotics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for PROCEPT BioRobotics are expected to grow in the coming year, from ($2.00) to ($1.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of PROCEPT BioRobotics is -22.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of PROCEPT BioRobotics is -22.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
PROCEPT BioRobotics has a P/B Ratio of 9.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About PROCEPT BioRobotics Stock (NASDAQ:PRCT)

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

PRCT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PRCT Stock News Headlines

March 21, 2024 | insidertrades.com

Insider Selling: PROCEPT BioRobotics Co. (NASDAQ:PRCT) EVP Sells 441 Shares of Stock

March 21, 2024 | insidertrades.com

Insider Selling: PROCEPT BioRobotics Co. (NASDAQ:PRCT) CFO Sells 1,024 Shares of Stock

April 18, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 16, 2024 | americanbankingnews.com

Contrasting SeaStar Medical (NASDAQ:ICU) & PROCEPT BioRobotics (NASDAQ:PRCT)

April 13, 2024 | americanbankingnews.com

PROCEPT BioRobotics (NASDAQ:PRCT) Sets New 12-Month High at $53.54

April 8, 2024 | msn.com

Experts Top 5 AI Stocks With Huge Potential

April 4, 2024 | globenewswire.com

PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas

April 2, 2024 | globenewswire.com

PROCEPT BioRobotics to Report First Quarter 2024 Financial Results on May 1, 2024 and Attend the 2024 Bank of America Healthcare Conference on May 15, 2024

April 18, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 20, 2024 | finance.yahoo.com

PROCEPT BioRobotics Corp (PRCT) President and CEO Reza Zadno Sells Company Shares

March 18, 2024 | finance.yahoo.com

PRCT Oct 2024 55.000 call

March 16, 2024 | ca.finance.yahoo.com

PRCT Apr 2024 50.000 put

March 8, 2024 | finance.yahoo.com

EVP, CLO, Corporate Secretary Alaleh Nouri Sells Shares of PROCEPT BioRobotics Corp (PRCT)

March 7, 2024 | finance.yahoo.com

Director Thomas Krummel Sells 20,000 Shares of PROCEPT BioRobotics Corp (PRCT)

March 1, 2024 | nasdaq.com

Noteworthy Wednesday Option Activity: ZM, PRCT, MSTR

March 1, 2024 | finance.yahoo.com

PROCEPT BioRobotics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

February 29, 2024 | ca.finance.yahoo.com

PRCT Jul 2024 70.000 call

February 29, 2024 | ca.finance.yahoo.com

PRCT Mar 2024 70.000 call

February 28, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Pliant Therapeutics (PLRX) and Viridian Therapeutics (VRDN)

February 28, 2024 | markets.businessinsider.com

Truist Securities Maintains Buy Rating for PROCEPT BioRobotics: Here's What You Need To Know

February 28, 2024 | finance.yahoo.com

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q4 2023 Earnings Call Transcript

February 28, 2024 | finance.yahoo.com

Q4 2023 Procept Biorobotics Corp Earnings Call

February 28, 2024 | investors.com

Bio Stock Procept BioRobotics Eyes Rare Buy Trigger After Earnings

February 27, 2024 | seekingalpha.com

PROCEPT BioRobotics Corporation 2023 Q4 - Results - Earnings Call Presentation

February 27, 2024 | benzinga.com

PROCEPT BioRobotics: Q4 Earnings Insights

February 27, 2024 | globenewswire.com

PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results

February 26, 2024 | markets.businessinsider.com

Piper Sandler Reaffirms Their Buy Rating on PROCEPT BioRobotics (PRCT)

See More Headlines

Receive PRCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PROCEPT BioRobotics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/18/2024
Next Earnings (Confirmed): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:PRCT
CUSIP: N/A
CIK: 1588978
Web: www.procept-biorobotics.com
Phone: 650-232-7200
Fax: N/A
Employees: 626
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $45.60
High Stock Price Target: $58.00
Low Stock Price Target: $37.00
Potential Upside/Downside: -10.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-105,900,000.00
Net Margins: -77.75%
Pretax Margin: -77.76%
Return on Equity: -46.59%
Return on Assets: -30.63%

Debt

Debt-to-Equity Ratio: 0.18
Current Ratio: 7.63
Quick Ratio: 6.77

Sales & Book Value

Annual Sales: $136.19 million
Price / Sales: 19.11
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.56 per share
Price / Book: 9.19

Miscellaneous

Outstanding Shares: 50,964,000
Free Float: 40,975,000
Market Cap: $2.60 billion
Optionable: Optionable
Beta: 1.01

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Dr. Reza Zadno Ph.D. (Age 69)
President, CEO & Director
Comp: $1.26M
Mr. Kevin Waters (Age 47)
Executive VP & CFO
Comp: $744.1k
Ms. Alaleh Nouri (Age 45)
EVP, Chief Legal Officer & Corporate Secretary
Comp: $713.61k
Mr. Hisham Shiblaq (Age 48)
Executive VP & Chief Commercial Officer
Comp: $757.2k
Mr. Mohan F. Sancheti (Age 60)
Senior Vice President of Operations
Mr. Barry Templin
Executive VP of Technology & Clinical Development
Mr. Matthew James Bacso C.F.A.
Vice President of Investor Relations
Ms. Stacey L. Porter (Age 48)
Chief People Officer
Mr. Bijesh Chandran
Senior Vice President of Regulatory Affairs & Quality Assurance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PRCT Stock Analysis - Frequently Asked Questions

Should I buy or sell PROCEPT BioRobotics stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PROCEPT BioRobotics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRCT shares.
View PRCT analyst ratings or view top-rated stocks.
What is PROCEPT BioRobotics' stock price target for 2024?: 6 Wall Street research analysts have issued twelve-month price objectives for PROCEPT BioRobotics' stock. Their PRCT share price targets range from $37.00 to $58.00. On average, they anticipate the company's stock price to reach $45.60 in the next year. This suggests that the stock has a possible downside of 10.7%.
View analysts price targets for PRCT or view top-rated stocks among Wall Street analysts.
How have PRCT shares performed in 2024?: PROCEPT BioRobotics' stock was trading at $41.91 at the beginning of the year. Since then, PRCT stock has increased by 21.9% and is now trading at $51.08.
View the best growth stocks for 2024 here.
When is PROCEPT BioRobotics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our PRCT earnings forecast.
How can I listen to PROCEPT BioRobotics' earnings call?: PROCEPT BioRobotics will be holding an earnings conference call on Wednesday, May 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.
How were PROCEPT BioRobotics' earnings last quarter?: PROCEPT BioRobotics Co. (NASDAQ:PRCT) issued its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.10. The company had revenue of $43.58 million for the quarter, compared to analysts' expectations of $41.79 million. PROCEPT BioRobotics had a negative net margin of 77.75% and a negative trailing twelve-month return on equity of 46.59%. The company's revenue was up 83.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.56) EPS.

What ETFs hold PROCEPT BioRobotics' stock?: ETFs with the largest weight of PROCEPT BioRobotics (NASDAQ:PRCT) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), ALPS Disruptive Technologies ETF (DTEC), Global X Robotics & Artificial Intelligence Thematic ETF (BOTZ) and BNY Mellon Innovators ETF (BKIV).iShares U.S. Medical Devices ETF (IHI).
What guidance has PROCEPT BioRobotics issued on next quarter's earnings?: PROCEPT BioRobotics issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $210.0 million-$210.0 million, compared to the consensus revenue estimate of $204.5 million.
When did PROCEPT BioRobotics IPO?: PROCEPT BioRobotics (PRCT) raised $126 million in an initial public offering on Wednesday, September 15th 2021. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share.
Who are PROCEPT BioRobotics' major shareholders?: PROCEPT BioRobotics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.39%) and Diversified Trust Co (0.03%). Insiders that own company stock include Alaleh Nouri, Frederic H Moll, Global Investors Lp Viking, Hisham Shiblaq, Kevin Waters, Morgan Colby Wood, Reza Zadno and Thomas M Krummel.
View institutional ownership trends.
How do I buy shares of PROCEPT BioRobotics?: Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRCT) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

PROCEPT BioRobotics (PRCT) Stock Price, News & Analysis

PROCEPT BioRobotics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About PROCEPT BioRobotics Stock (NASDAQ:PRCT)

PRCT Stock Price History

PRCT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PRCT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™